Treatment of Myasthenia Gravis exacerbation with intravenous immunoglobulin - A randomized double-blind clinical trial
Treatment of Myasthenia Gravis exacerbation with intravenous immunoglobulin - A randomized double-blind clinical trial
复制标题
DOI：
10.1001/archneur.62.11.1689
复制
发表时间：
2005-11-01
影响因子：
--
通讯作者：
Chevret, S
中科院分区：
文献类型：
--
作者：
Gajdos, P;Tranchant, C;Chevret, S
Background: The optimal dose of intravenous immunoglobulin (IVIG) in acute exacerbation of myasthenia gravis remains unknown. Increasing the treatment duration might provide added efficacy.Objective: To determine the optimal dose of IVIG for treating myasthenia gravis exacerbation.Design: Randomized double-blind placebo-controlled multicenter trial designed to demonstrate superiority of the 2 g/kg dose over the 1 g/kg dose of IVIG, conducted between November 13, 1996, and October 26, 2002.Participants: One hundred seventy-three patients aged 15 to 85 years with acute exacerbation of myasthenia gravis.Intervention: Participants were randomly assigned to receive 1 g/kg of IVIG on day 1 and placebo on day 2 (group 1) vs 1 g/kg of IVIG on 2 consecutive days (group 2).Main Outcome Measure: Improvement in the myasthenic muscular score after 2 weeks.Results: The mean improvements in the myasthenic muscular scores after 2 weeks were 15.49 points (95% confidence interval, 12.09-18.90 points) in group 1 and 19.33 points (95% confidence interval, 15.82-22.85 points) in group 2. However, the difference between the 2 groups was not significant (effect size, 3.84 [95% confidence interval, -1.03 to 8.71]; P = .12).Conclusion: This trial found no significant superiority of 2 g/kg over 1 g/kg of IVIG in the treatment of myasthenia gravis exacerbation.
